International Cycling

8 riders fail drug tests at Tour of Colombia

2017-11-29 21:03
Cycling (File)

Paris - Eight cyclists returned positive doping tests during August's Tour of Colombia, seven used a variant of the blood booster EPO known as CERA, the International Cycling Union said on Wednesday.

A UCI press release revealed the doping controls had been carried out on the basis of intelligence that had been uncovered.

CERA is effective for up to a month and does not show up in urine tests, but it can be detected by blood tests for 5-6 days after injection.

Luis Alberto Largo, Jonathan Paredes, Edward Diaz, Fabio Montenegro, Luis Camargo, Fabian Lopez and Oscar Soliz all tested positive for CERA on August 1 or 2 while Juan Carlos Cadena returned a positive testosterone sample August 11.

Soliz, who is Bolivian, was the best of the eight, finishing eighth in the general classification. The other seven are all Colombian.

All eight have been provisionally suspended pending a ruling and all may appeal for their 'B' samples to be tested.

The most recent positive test for CERA resulted in cyclist Joao Marcelo Pereira Gaspar being hit with a four-year ban.

Read more on:    cycling
NEXT ON SPORT24X

What To Read Next

 

Read News24’s Comments Policy

Live Video Streaming
Video Highlights
Sport Talk

 
 
Men
Women
Love 2 Meet
Sport24 on Twitter

Follow Sport24 news on Twitter

Featured

The 2017/18 Absa Premiership season is under way. Can Bidvest Wits defend their title? Will Soweto giants Kaizer Chiefs or Orlando Pirates emerge victorious? Or will the bookies' favourites, Mamelodi Sundowns, taste success for a record eighth time? Stay glued to Sport24 to find out!

Latest blogs
Vote

Besides the 'Big 3' of rugby, cricket and soccer, which of the 'smaller' sports in South Africa do you enjoy the most?

Twitter Follow Sport24 on Twitter

Facebook "Like" Sport24's Facebook page

WIN Enter and win with Sport24!

BlackBerry Stay in the loop on your BlackBerry

RSS Feeds Sport news delivered really simply.

 
There are new stories on the homepage. Click here to see them.